In the “streaming” category, YouTube remained the clear leader with 57.4% of traffic. It was followed by Instagram (17.4%), ...

Mindhunter was and remains one of the best Netflix original series in the streamer's history. Here's what the lead actors ...

The documentary examines the disappearance of eight-month-pregnant Laci Peterson in 2002 and the investigation that ...

Despite fan demand for a third season, Mindhunter came to an end after just two seasons and it will never come back.

In June 2025, actor Holt McCallany said David Fincher sees a chance for Mindhunter to return as three two-hour movies, ...

A mysterious and deeply unsettling addition is heading to the streaming giant, promising to keep true-crime fanatics up all night.

Mindhunter then, Mindhunter now, and Mindhunter in the future, hopefully.

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment BRUKINSA plus ...

The official commissioning of the modernized Baku-Tbilisi-Kars (BTK) railway at the Akhalkalaki Railway and Logistics Complex in Georgia marks a significant milestone not only for Azerbaijan, Georgia ...

Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that is set to go head-to-head against Eli Lilly’s Jaypirca in a phase 3 trial.

Roche is preparing to file one BTK-targeting drug for approval, and has just added another with potential across oncology, immunology, and neurology via a deal with Nurix Therapeutics. The licensing ...

Roche is wagering billions of dollars on a medicine that trashes a troublesome protein instead of stifling its activity. The Swiss drugmaker on Monday reached a deal with Nurix Therapeutics to ...